

Novel Fusion Peptide-Mediated siRNA Delivery Using Self-Assembled Nanocomplex

Yeong Chae Ryu

Incheon National University

Kyungah Kim

Incheon National University

Byoung Choul Kim

Incheon National University

Hui-Min David Wang

National Chung Hsing University

Byeong Hee Hwang (✉ bhwang@inu.ac.kr)

Incheon National University <https://orcid.org/0000-0003-1349-6351>

Research

Keywords: Nanocomplex, self-assembly, peptides, siRNA, drug delivery, gene therapy

Posted Date: August 11th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-55537/v1>

License:   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published on February 12th, 2021. See the published version at <https://doi.org/10.1186/s12951-021-00791-x>.

Abstract

Background: Gene therapy using siRNA can be a new potent strategy to treat many incurable diseases at the genetic level, including cancer and viral infections. Treatments using siRNA essentially requires an efficient and safe method of delivering siRNA into cells while maintaining its stability. Thus, we designed novel synergistic fusion peptides, i.e., SPACE and oligoarginine.

Results: Among the novel fusion peptides and siRNAs, nanocomplexes have outstanding cellular uptake and gene silencing effect *in vitro* and high stability and retention effect of siRNAs *in vivo*. Oligo arginine could attract siRNAs electrostatically to form stable and self-assembled nanocomplexes, and the SPACE peptide could interact with the cellular membrane via hydrogen bonding. Therefore, nanocomplexes using fusion peptides showed improved and evident cellular uptake and gene silencing of Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) via the lipid raft-mediated endocytosis pathway, especially to the HDFn cells of the skin, and all of the fusion peptides were biocompatible. Also, intratumorally injected nanocomplexes had increased stability and retention of siRNAs at the site of the tumor.

Conclusions: The new nanocomplex strategy could become a safe and efficient platform for the delivery of siRNAs into cells and tissues to treat various target diseases through gene therapy.

Background

RNA interference (RNAi) has been demonstrated to be a promising gene therapy approach that regulates the expression of specific genes [1–3]. As an RNAi mediator, short-interfering RNA (siRNA) is a double-stranded molecule that is composed of about 21–23 nucleotides, and it is designed as a sequence complementary to the target mRNA. The exogenously penetrated siRNAs activate the RNA-induced silencing complexes (RISC) in the cytoplasm and result in outstanding selective mRNA inhibition with low cytotoxicity. Therefore, gene therapy using siRNA can be a new potent strategy to treat cancer, viral infectious diseases, and local diseases at the genetic level. However, a significant barrier to siRNA delivery is that its hydrophilic nature results in low uptake efficiency into the cell membranes that are composed of phospholipid bilayers [4, 5]. Also, the siRNA is vulnerable to degradation by the large amounts of nucleases that are present in the cytoplasm or interstitial fluid [6]. Therefore, it is essential to develop an efficient, safe, and stable method of delivering siRNA.

To date, several methods have been developed to deliver siRNA, and they can be categorized as either physical or chemical methods [7]. The physical methods could deliver siRNAs using specialized equipment, e.g., microinjectors, gene guns, electroporators, sonoporators, lasers, and magnetofactors [8]. However, physical methods have limitations for various applications due to the need for special equipment, non-specificity of the delivery of siRNA, and the instability of siRNA that is delivered. Also, chemical methods could deliver siRNAs by using carriers that are capable of interacting with siRNAs and transferring siRNA into cells. The potential types of carriers include lipoplex, polyplex, dendrimer, peptide, and various nanoparticles [9–13]. These carriers could enhance the stability of siRNAs and the efficiency

of delivery. However, the chemical methods have the disadvantages of limited delivery efficiency and the potential toxicity of the chemicals. Therefore, an ideal siRNA delivery method requires enhanced delivery efficiency, biosafety, and siRNA stability.

Recently, peptides have been studied intensively as attractive siRNA carriers due to their structural and functional versatility, potential biocompatibility, and their ability to target cells. Primarily, cell-penetrating peptides (CPPs) have been known to penetrate cell membranes effectively. The TAT sequence originated from the Tat protein of the human immunodeficiency virus (HIV) [14–16]. Oligoarginine is positively charged, and it can assist cellular internalization by forming a hydrogen bond with the sulfate of the cell membrane and the phosphate group of nucleic acid [17–21]. The histidine-rich peptide was confirmed using the efficient delivery of siRNA [22]. In addition, the development of the phage display technique made it possible for us to find new types of cell-penetrating peptides. For example, the skin permeating and cell entering (SPACE) peptides have a superior ability to facilitate the penetration of conjugated cargoes into the epidermis and dermis [23]. However, limited delivery efficiency was observed for a single peptide, and some peptides, such as SPACE, must undergo the additional conjugation reaction. Therefore, for a facile and useful siRNA carrier, a method is required that provides enhanced delivery efficiency without further reaction.

Herein, we report our design of novel fusion peptides and the results of our investigation of their potential as carriers for the delivery of siRNA. The three fusion peptides were composed of SPACE and cationic oligoarginine (R7, R11, and R15) linked by the GCG sequence in Additional file 1: Table S1 [24]. The self-assembled nanocomplex was identified between each peptide and siRNA without any conjugation. Also, each nanocomplex was characterized in terms of size, zeta-potential, and siRNA stability. The cellular uptake efficiency of each nanocomplex was measured using FACS and fluorescence microscopy. Intracellular co-localization or dissociation of the nanocomplex was analyzed using a confocal microscope. The nanocomplex-mediated GAPDH knockdown was assessed using the mRNA expression level. And, the biocompatibility of each nanocomplex was checked using a lactate dehydrogenase assay of human dermal fibroblast cells. Also, the internalization pathway of the siRNA/S-R15 nanocomplex was analyzed using FACS and endocytosis inhibitors. Finally, the pharmacokinetic property of the Cy3-labeled siRNA/S-R11 nanocomplex was studied using intratumoral injection to xenografted BALB/c nude mice.

Results

Novel fusion peptides were designed using SPACE and oligoarginine with different repeat numbers for siRNA delivery through self-assembled nanocomplexes. The newly-synthesized fusion peptides successfully formed stable and spontaneous nanocomplexes with siRNAs mainly via electrostatic attraction. All of the nanocomplexes enhanced the cellular uptake of siRNAs such that it was similar to or better than commercialized Lipofectamine™ 2000. Co-localization and cellular internalization of the siRNA/S-R15 nanocomplexes were verified peripherally around the nucleus. Among fusion peptides, the S-R15 nanocomplex induced the highest knockdown of GAPDH mRNA expression, i.e., it was comparable to that of commercialized Lipofectamine™ 2000. Also, each fusion peptide was biocompatible with

human dermal fibroblast cells at the concentration of 200 µg/mL. The primary penetration mechanism of the S-R15 nanocomplex was identified as lipid raft-mediated endocytosis. In xenografted BALB/c nude mice, the nanocomplex stabilized and kept the locally administered siRNAs in the tumor site.

Confirmation and characterization of siRNA/peptide nanocomplexes

The formation of siRNA/peptide nanocomplexes at different N/P ratios was confirmed by electrophoretic mobility shift (Fig. 1a). As a result, R11, S-R7, S-R11, and S-R15 retarded the siRNA band. As fusion peptides, S-R7, S-R11, and S-R15 showed complete retardation of siRNA at ratios over 20:1, 10:1, and 40:1, respectively. Partial retardation was observed with R11, a single peptide, based on the blur siRNA band at ratios over 30:1. However, SPACE and TAT did not retard the siRNA band at all for any of the N/P ratios. Because TAT, a single peptide, did not form a condensed nanocomplex with siRNA, peptides other than the TAT peptide were used for the following experiments.

The size and zeta potential of the nanocomplex were measured three times using dynamic light scattering (Fig. 1b and Additional file 1: Table S2). Nanocomplexes using SPACE, R11, S-R7, S-R11, and S-R15 had average sizes of 648, 414, 327, 457, and 287 nm, respectively. Nanocomplexes that used SPACE, R11, S-R7, S-R11, and S-R15 had average polydispersity indexes (Pdl) of 0.89, 0.23, 0.22, 0.23, and 0.04, respectively, and they had average zeta potentials of -28.3, -11.8, 5.2, 6.0, and 6.1, respectively.

The stability of siRNA in nanocomplexes was assessed during the incubation of the serum (Fig. 1c). First, each nanocomplex was incubated with 10% FBS to simulate a cell culture condition. Interestingly, the nanocomplexes that used S-R15 and S-R11 maintained the siRNA stability for 96 hours. However, the siRNA bands of the other nanocomplexes disappeared gradually over time. The decomposition rates in 10% FBS increased in the order of S-R15, S-R11, R11, free siRNA, S-R7, and SPACE. Subsequently, each nanocomplex was incubated with 50% FBS to simulate extreme decomposition conditions. Interestingly, only the S-R15 nanocomplex maintained siRNA stability for 48 hours, and the siRNA bands of the other nanocomplexes disappeared gradually and disappeared completely in 24 hours. The decomposition rates in 50% FBS increased in the order of S-R15, S-R11, R11, S-R7, free siRNA, and SPACE. S-R15 showed the best siRNA stability in the nanocomplex for both conditions.

Evaluation of the *in vitro* cellular uptake of the nanocomplexes

The cellular uptake of each nanocomplex was observed using a fluorescence microscope in HeLa cells (Fig. 2a). The images represented Cy3-labeled siRNA of orange fluorescence, the nucleus of blue fluorescence, and the actin filament of green fluorescence. Figure 2a shows that orange fluorescence was observed inside the cells in the images of Lipofectamine™ 2000 (the second row), R11 (the fourth row), S-R7 (the fifth row), S-R11 (the sixth row), and S-R15 (the seventh row). Nanocomplexes using fusion

peptides showed orange spots in the cytosol. However, Lipofectamine™ 2000 showed dispersed orange fluorescence within the cytosol, and an R11 nanocomplex showed orange fluorescence spots that were spread within the cytosol. In contrast, free siRNA and SPACE nanocomplex did not show any orange fluorescence in the first and third rows of Fig. 2a.

Also, co-localization and cellular internalization of nanocomplexes were confirmed using a confocal microscope with super-resolution at the single-molecule level (Figs. 2b and c). The Cy3-modified siRNA and FITC-modified S-R15 peptide in the images were represented as magenta fluorescence and green fluorescence, respectively (Fig. 2b). The siRNA and S-R15 peptides were co-localized at the white spot designated by the arrow in the merged image. The nanocomplexes of the Cy3-labeled siRNA and FITC-labeled S-R15 were localized intracellularly in the Z-stack image of HeLa cells (Fig. 2c). The arrows point to the spots where white fluorescence was located in the cytoplasm around the nucleus.

The cellular uptake efficiency of each nanocomplex was evaluated using flow cytometry in HDFn (Fig. 2d), HeLa, and HaCaT cells (Additional file 1: Fig. S1). Using Cy3-labeled siRNA, the fluorescent cells with free siRNA, and each condition are exhibited in red and green populations, respectively. The percentage represented the population of fluorescence-positive cells divided by the total cells. Nanocomplexes using S-R7, S-R11, and S-R15 showed the high cellular uptake efficiencies of 99.8%, 99.8%, and 99.6% in the HDFn cells (Fig. 2d), 95.6%, 85.2%, and 78.2% in the HeLa cells, and 95.5%, 79.1%, and 99.9% in the HaCaT cells (Additional file 1: Fig. S1). These efficiencies were higher than 87.0% in HDFn cells, 71.3% in HeLa cells, and 79.8% in HaCaT cells treated by Lipofectamine™ 2000 as a commercialized positive control. The nanocomplex using R11, a single peptide, showed cellular uptake efficiency of 88.5% in HDFn cells, 92.6% in HeLa cells, and 99.8% in HaCaT cells. In contrast, the nanocomplex using SPACE showed negligible cellular uptake efficiency in HDFn cells (0.3%), HeLa cells (4.5%), and HaCaT cells (0.2%).

Gene silencing effect

The siRNA delivered by the nanocomplex knocked down the GAPDH mRNA expression in the HeLa and HaCaT cells using quantitative RT-PCR analysis (Fig. 3a and Additional file 1: Table S3). In the HeLa cells, the nanocomplex using S-R15 reduced the relative GAPDH mRNA expression of 38.7% compared to that of free siRNA. This knockdown percentage was significantly different from that of SPACE (p -value = 0.011) and comparable to 35.3% using Lipofectamine™ 2000. Nanocomplexes using R11, S-R7, and S-R11 knocked down the GAPDH mRNA expression to 52.6, 56.8, and 51.3%, respectively. Also, the nanocomplex using SPACE induced the least knockdown of 72.8%. In the HaCaT cells, the 49.8% knockdown using S-R15 was comparable to 40.8% of Lipofectamine™ 2000 without a statistically significant difference. These results indicated that these nanocomplexes could knock down mRNA expression in different types of cells, including cancer cells and keratinocyte cells in the skin.

Biocompatibility of fusion peptides

The biocompatibility of fusion peptides was verified using a lactate dehydrogenase (LDH) assay with HDFn cells (Fig. 3b and Additional file 1: Table S4). Each LDH activity was normalized with the LDH

activity using a lysis buffer as 100%. The normalized LDH activity of various concentrations of each fusion peptide did not show any significant cytotoxicity compared to the negative control. Therefore, fusion peptides were deemed to be biocompatible and could be applied to the cells at concentrations of less than 200 µg/mL.

Cellular uptake pathway of the nanocomplex

The cellular uptake pathway of the nanocomplex was analyzed using endocytosis inhibitors and flow cytometry (Fig. 4). On the graphs, cell distributions without an inhibitor were represented as red, and those with an inhibitor were represented as green. The figures of the first row only expressed the penetrating inhibition of the FITC-labeled S-R15 peptide or that of the nanocomplex (Fig. 4). When the reference point was taken at 89.5% in red distribution, the population of cells decreased to 53.1% in chlorpromazine and to 68.3% in methyl-β-cyclodextrin. Chlorpromazine and methyl-β-cyclodextrin are known as inhibitors of clathrin-mediated endocytosis and lipid raft-mediated endocytosis, respectively. In contrast, the cell populations showed no decrease in the cases of cytochalasin D and Filipin III. Cytochalasin D and Filipin III are known as inhibitors of phagocytosis/micropinocytosis and caveolae-mediated endocytosis, respectively. Thus, the penetration of the S-R15 peptide only or the nanocomplex was inhibited dominantly by clathrin-mediated and lipid raft-mediated endocytosis.

The figures of the second row represented the penetrating inhibition of the Cy3-labeled siRNA nanocomplex. When the reference point was set at 89.2% in red distribution, the cell population decreased to 68.2% prominently in the lipid raft-mediated endocytosis inhibitor, methyl-β-cyclodextrin. In contrast, the other cell populations with other inhibitors showed no decreases. Therefore, the permeation of the siRNA nanocomplex was inhibited dominantly by lipid raft-mediated endocytosis. In summary, both experiments using FITC-labeled S-R15 peptide only or nanocomplex and Cy3-labeled siRNA nanocomplex showed consistency of inhibition in lipid raft-mediated endocytosis.

Intratumoral injection of the nanocomplex to xenografted mice

The pharmacokinetic property of siRNA was assessed using the intratumoral injection of the nanocomplex to xenografted mice. Fluorescence images were taken of the Cy3-labeled siRNA/S-R11 nanocomplex (Fig. 5). Immediately after the injection of siRNA (0 h), the higher fluorescence intensity of Cy3-labeled siRNAs was observed in the core region of the right tumor with the nanocomplex than in the region of free siRNAs without the nanocomplex (Fig. 5a). Also, over time, the fluorescence area and intensity of the siRNAs without the nanocomplex were diminished quickly. In contrast, the fluorescence area and intensity of siRNAs in the nanocomplex decreased gradually and remained in the tumor site for at least 4 hours.

The relative mean intensity of the fluorescence of the nanocomplex group did not decrease significantly from the initial value over time. In contrast, the free siRNA group had an approximately 50% reduction in relative mean intensity after 1 hour (Fig. 5b and Additional file 1: Table S5). Relative mean fluorescence

intensities between the two groups showed statistically significant differences at all points. The p -values were 0.017, 0.009, 0.012, and 0.007 for 1, 2, 3, and 4 hours, respectively. The relative integrated density was calculated using area multiplied by the fluorescence intensity unit divided by the initial value. The relative integrated density of the nanocomplex group remained about 50% for 4 hours, while the free siRNA group simultaneously represented the minimal integrated density (Fig. 3c and Additional file 1: Table S6). The relative integrated density of most conditions showed statistically significant differences between the two groups. The p -values were 0.019, 0.132, 0.007, and 0.034 for 1, 2, 3, and 4 hours, respectively. To summarize, the nanocomplex increased the *in vivo* stability of the siRNAs and enhanced the retention effect of the locally-administered siRNAs.

Discussion

Overall, the nanocomplexes that used novel fusion peptides exhibited outstanding cellular uptake and gene silencing effect *in vitro* and high stability and retention effect of siRNAs *in vivo*. These excellent results could be explained based on the intrinsic properties of the nanocomplex, i.e., its uniform nanosize, weakly positive surface charge, stability, endosomal escape of arginine residues, and strong adhesion. It was assumed that properties of the nanocomplex were caused by the synergistic effects between the oligoarginine, which had a strong positive charge, and the SPACE peptide, which showed effective penetration of the cells [23]. In detail, the oligoarginine of the fusion peptide could attract siRNAs as a driving force to form a nanocomplex. And, as the arginine residues increased, the stability of the nanocomplex increased. Also, it could help to exhibit a weakly positive surface charge and to escape endosomes [25]. In addition, because the SPACE peptide could contain many hydroxyl, sulfhydryl, and amino groups, it could form hydrogen bonds with siRNAs or peptides. Hydrogen bonding of SPACE could enhance the stability of the nanocomplex and interact with the cellular membrane and extracellular matrix (ECM), including keratin [26]. As a result, the interaction with the cellular membrane and ECM could increase the cellular uptake or the retention of tissue. Therefore, the fusion strategy of oligoarginine and SPACE peptides demonstrated synergistic properties complementary to single peptides.

The interactions between peptides and siRNAs can be explained based on their respective properties. First, R11 and fusion peptides with strong positive charges could form self-assembled and condensed nanocomplexes with siRNAs based on the complete retardation of the siRNA band. In contrast, SPACE and TAT, with their weaker positive charges, could not build a condensed nanocomplex with siRNA based on almost no retardation of the siRNA band. These results coincided with the result using oligoarginine [27], and they indicated that a positively-charged region with high density was essential for the formation of nanocomplexes with siRNAs. Using the amino acid analysis via the peptide 2.0 web (www.peptide2.com), the percentages of positive residues were 100% of R11, 9.1% among the 11 amino acids of SPACE, and 88.9% among the 9 amino acids of TAT. The fusion peptides' percentages of positive residues were 38.1% of S-R7, 48% of S-R11, and 55.2% of S-R15. The successive and longer positive charge of the peptide could increase the electrostatic attraction with the negatively-charged siRNAs and result in the formation of a stable nanocomplex. Note that SPACE contained a hydrophobic alanine, two

cysteines (SH), two threonines (OH), two glycines, a serine (OH), two glutamines (NH₂), and histamine (NH). These dominant functional groups could form hydrogen bonds and help to maintain the condensed nanocomplexes.

Characterization of the nanocomplexes could help in understanding the reasons for the enhanced cellular uptake and gene silencing. Interestingly, based on the light-scattering analysis, the S-R15 peptide formed the smallest and most uniform nanocomplex with a weakly positive zeta potential. The S-R7 and S-R11 nanocomplexes had small and medium in size, respectively, with acceptable Pdl and weak positive charges. The weak positive charges of the three nanocomplexes meant that the fusion peptides were exposed to the surface of the nanocomplex. Also, a slightly positive charge and uniform size could enhance the cellular internalization of the nanocomplex, as reported earlier [28]. Also, the R11 nanocomplex had a medium size, acceptable Pdl, and negative zeta potential. Its negative zeta potential could mean that the R11 peptide did not completely shield the negative charge of the siRNAs on the surface of the nanocomplex. In contrast, the SPACE peptide appeared to fail to form a condensed nanocomplex based on its large size, high polydispersity index, and highly negative zeta potential. Consequently, the strategy of fusion peptides enabled the building of nanocomplexes with the proper nanosize, Pdl, and weakly positive zeta potential, which could enhance the cellular uptake.

The stability of the nanocomplex could be explained based on the properties of the peptides with different arginine lengths. S-R15 formed the most stable nanocomplex, which might show increased stability of cellular uptake. The stability of nanocomplexes with siRNAs could be affected by charge neutralization and cohesive strength caused by the electrostatic attraction between the peptides and the siRNAs [29]. That is, more extended and successive positive residues of S-R15 could attract siRNAs and effectively shield the negative charges of siRNA. In addition, the stability of the SPACE part of the S-R11 enhanced nanocomplex was comparable to that of the R11 peptide. This result meant that the SPACE peptide could increase the stability of the nanocomplex via hydrogen bonds with siRNAs or peptides.

Clear evidence has been presented that supports the cellular internalization and co-localization of the nanocomplex. Z-stack images showed cellular internalization based on the fluorescence spot in the middle height of a cell (Fig. 2c). Co-localization of the nanocomplex was identified via white fluorescence merged between the magenta fluorescence of the siRNAs and the green fluorescence of the S-R15 (Fig. 2b). The co-localized siRNA/S-R15 nanocomplexes were distributed peripherally around the nucleus in particle-like forms within the cytoplasm. These forms might represent endosomes that contain nanocomplexes. However, the spread of the magenta fluorescence might indicate that the siRNAs dissociated from the nanocomplexes after the endosomes escaped. These results coincided with the co-localization or dissociation of nanocomplexes, as reported earlier [27, 30–32].

The efficiency of the cellular uptake of nanocomplexes was different depending on the cell lines. Interestingly, nanocomplexes with fusion peptides showed the highest cellular internalization to human dermal fibroblast cells, i.e., more than 99% (Fig. 2d). These efficiencies were higher than those of the Lipofectamine™ 2000 or the R11 nanocomplex. Similarly, in the HeLa and HaCaT cells, cellular uptakes of

fusion peptide nanocomplexes were similar to or higher than that of Lipofectamine™ 2000 (Additional file 1: Fig. S1). In contrast, cellular uptakes of the fusion peptide nanocomplexes were similar to or lower than that of the R11 nanocomplex. As a result, nanocomplexes using fusion peptides could be taken up more efficiently by skin cell lines. These results could be explained in that the SPACE peptide could effectively penetrate skin cells [23].

The endocytosis pathway of the S-R15 peptide does not agree with the micropinocytosis of the SPACE peptide [23], but it does agree with the clathrin-mediated endocytosis of arginine-rich peptides [33]. This result indicated that S-R15 peptide dominantly could bind the receptors of the surface of a specific cell, resulting in the clustering formed by the assembly of clathrin [33]. However, the endocytosis pathway of the siRNA/S-R15 nanocomplex was different from that of only the S-R15 peptide. The siRNA/S-R15 nanocomplex was associated with the cell membrane and became trapped in lipid raft. The possible reasons could be the large size of the S-R15 nanocomplex and the fact that the strong interactions between oligoarginine and siRNA weakened the binding to the receptors on the surfaces of specific cells. This result coincides with the endocytosis pathway of arginine-rich peptide fusion proteins or large cargo [34].

Conclusions

Nanocomplexes, among novel fusion peptides and siRNAs, exhibited outstanding cellular uptake and gene silencing effect *in vitro* and high stability and retention effect of siRNAs *in vivo*. These excellent results could be explained by the synergistic effect between the oligoarginine and SPACE peptides. Oligoarginine could electrostatically attract siRNAs to form nanocomplexes, and the SPACE peptide could interact with the cellular membrane via hydrogen bonding. Therefore, nanocomplexes using fusion peptides showed improved and evident cellular uptake and gene silencing of GAPDH via the lipid raft-mediated endocytosis pathway, especially to skin HDFn cells. In addition, all of the fusion peptides were biocompatible. Also, intratumorally injected nanocomplexes showed increased stability and retention of siRNAs in the local tumor site. Therefore, the new nanocomplex strategy could become a safe and efficient siRNA delivery platform to treat various target diseases through gene therapy.

Methods

Materials

AccuTarget™ GAPDH positive control siRNA was provided by Bioneer Co. (Daejeon, South Korea), and Cy3-labeled siRNA was synthesized by GenePharma Co., Ltd. (Shanghai, China) in duplex form and purified by HPLC. All single and fusion peptides were synthesized by GL Biochem, Ltd. (Shanghai, China) with more than 95% purity. Hank's balanced salt solution (HBSS) was obtained from Life Technologies (CA, USA). Agarose and 10,000X TopRed Nucleic Acid Gel Stain were purchased from GenomicBase (Seoul, South Korea). Tris (Glenthams Life Sciences Ltd., Corsham, UK), acetic acid (glacial) (Merck, Darmstadt, Germany), and EDTA (GenomicBase, Seoul, South Korea) were used for the 1X TAE buffer.

Heparin sodium salt (from porcine intestinal mucosa) was purchased from Sigma-Aldrich (MO, USA). 6X DNA loading dye was procured from Biofact Co., Ltd. (Daejeon, South Korea). For cell cultures, we used Dulbecco's Modified Eagle's Medium (DMEM; Corning, MA, USA), fetal bovine serum (FBS; PAN Biotech, Bavaria, Germany) and penicillin-streptomycin (Life Technologies, CA, USA). Opti-MEM™ and 0.25% trypsin-EDTA (1X) were obtained from Thermo Fisher Scientific (MA, USA). Lipofectamine™ 2000 reagent was purchased from Invitrogen (CA, USA). Hoechst 33342 (Invitrogen, CA, USA), Flamma® 496 Phalloidin (BioActs, Incheon, South Korea) and SiR-actin kit (Cytoskeleton, Inc., CO, USA) were used for fluorescent labeling. 10% formalin solution (Sigma-Aldrich, MO, USA), Triton X-100 (Bio-Rad Laboratories, Inc., CA, USA) and bovine serum albumin (BSA; Generay Biotech Co., Ltd., Shanghai, China) were used for fluorescent imaging. Nuclease-free water was purchased from Integrated DNA Technologies, Inc. (IA, USA). Tri-RNA reagent (Favorgen Biotech Co., Kaohsiung, Taiwan), chloroform (Sigma-Aldrich, MO, USA), isopropanol (Molecular biology grade; Fisher Scientific, NH, USA), and absolute ethanol (Molecular biology grade; Fisher Scientific) were used for the extraction of RNA. ReverTra Ace® qPCR RT Master Mix with gDNA Remover kit and THUNDERBIRD® SYBR® qPCR Mix (TOYOBO Co., Ltd., Osaka, Japan) were procured for cDNA synthesis and quantitative real-time PCR. The CytoTox 96® Non-radioactive cytotoxicity assay kit was obtained from Promega (WI, USA). Chlorpromazine hydrochloride, methyl- β -cyclodextrin, cytochalasin D (from *Zygosporium mansonii*), and Filipin III (from *Streptomyces filipinensis*) endocytosis inhibitors were purchased from Merck (Darmstadt, Germany) for the mechanism study. All cell culture flasks and plates were purchased from NEST Biotechnology Co., Ltd (Wuxi, China). For the *in vivo* studies, isoflurane (Hana Pharm. Co., Ltd., Hwaseong, South Korea) as an anesthetic and 31-gauge needle insulin syringes (BD, NJ, USA) were used.

Preparation of siRNA/peptide nanocomplexes

GAPDH-siRNA was dissolved in HBSS as 1 μ M, and all peptides were dissolved in HBSS or distilled water at 1–2 mg/mL. The sequences of all peptides are summarized in Additional file 1: Table S1. The fusion peptides designed in this study have a GCG linker between SPACE and the oligoarginine peptides. Fusion peptides and siRNAs in HBSS buffer formed the self-assembled nanocomplexes under incubation at room temperature (25 °C) for 30 minutes with appropriate nitrogen/phosphate (N/P) ratio. The N/P ratio was derived using the molar ratio of amine groups in the cationic peptides to those of phosphate groups in the RNA.

Gel retardation assay

The formation of siRNA/peptide nanocomplexes was confirmed by gel retardation assay. Total 10 μ L nanocomplexes of 10 pmol siRNA and each peptide were self-assembled with a range of N/P ratios (1:1, 5:1, 10:1, 20:1, 30:1, 40:1, 50:1, and 100:1) as mentioned above. After adding 6X loading dye, the 12 μ L nanocomplexes were loaded into the 2% agarose gel (w/v) prepared in 1X TAE buffer (40 mM tris, 20 mM acetic acid, 1 mM EDTA, pH = 8.6) with 10,000X TopRed Nucleic Acid Gel Stain for visualization. Gel running was performed at 100 V for 30 minutes using the Mupid-2plus electrophoresis system (Optima Inc., Tokyo, Japan). Pictures of the electrophoretic mobility shift of the nanocomplexes were taken by the ChemiDoc™ XRS + System (Bio-Rad, CA, USA).

Measurement of the size and zeta potential of nanocomplexes

The size and zeta potential of the nanocomplexes were measured by dynamic light scattering (DLS). Based on the results of the previous gel retardation assay, a 20:1 N/P ratio was determined for the rest of the experiments due to the stable nanocomplex formation of all fusion peptides. 200 pmol siRNA and each peptide were self-assembled at a 20:1 N/P ratio, as described above. After 30 minutes, the nanocomplexes were diluted with HBSS to a final siRNA concentration of 200 nM. Then, the 200 nM solution was filtered with a 0.45- μm syringe filter (GVS, Bologna, Italy). After vortexing for 30 seconds, 1 mL of the nanocomplexes was loaded into a cuvette (Ratiolab, Dreieich, Germany) to measure the size and disposable folded capillary cell (Malvern Panalytical, Ltd., Malvern, UK) to measure the zeta potential. The size and zeta potential of the nanocomplexes were measured using a Zetasizer Nano ZS (Malvern Instruments, Ltd., Worcestershire, UK).

Stability of siRNA/peptide nanocomplexes in serum

The stability of the siRNA in nanocomplexes was confirmed using agarose gel electrophoresis. 100 pmol of siRNAs and peptides (20:1 N/P ratio) were self-assembled for 30 minutes at room temperature. Then, the nanocomplexes in 10% (v/v) FBS were incubated at 37 °C, and 20 μL of each sample were collected at 24, 48, 72, and 96 hours. However, the nanocomplex in 50% (v/v) FBS was incubated at 37 °C, and 20- μL samples were collected at 4, 8, 12, 24, and 48 hours. The siRNAs were dissociated from the nanocomplexes using incubation at 37 °C for 30 minutes after the addition of 4 μL of 1 mg/mL heparin. After mixing the 6X loading dye to each sample, 24 μL samples were loaded into 2% agarose gel with 1X TAE buffer in Mupid-2plus. Gel running was performed for 30 minutes at 100 V. The remaining siRNA was analyzed by the gel documentation system LSG 1000 (iNtRON Biotechnology, Seongnam, South Korea).

Cellular uptake efficiency using flow cytometry

Human cervical cancer HeLa, human dermal fibroblasts neonatal (HDFn), and immortal keratinocyte cell line HaCaT were cultured in DMEM medium supplemented with 10% FBS and 1% penicillin-streptomycin at 37 °C in a humidified incubator that contained 5% CO_2 (Esco Micro Pte. Ltd., Changi, Singapore). 3.0×10^5 cells were added to each well of a 6-well plate and incubated at 37 °C in a 5% CO_2 incubator overnight. After the nanocomplex formation of the final 200 nM Cy3-labeled IL10-siRNA and peptides (20:1 N/P ratio) in serum-reduced Opti-MEM™, 325 μL of the nanocomplex were added to each well and incubated for 4 hours at 37 °C in a 5% CO_2 incubator. The wells were washed twice with 1 mL of pre-warmed phosphate-buffered saline (PBS). After 200 μL treatment of 0.25% trypsin-EDTA for 2 minutes, 2 mL of fresh DMEM medium were added. The suspended cells were centrifuged at $360 \times g$ for 5 minutes. After the supernatant was removed, the cells were washed with PBS twice under the same conditions. The final cell pellets were resuspended in ice-cold PBS and analyzed using a flow cytometer (Gallios; Beckman Coulter, CA, USA).

Observation of cellular uptake using fluorescence microscopy

HeLa cells were seeded into a 24-well plate at the number of 1.0×10^5 cells per well and incubated overnight at 37 °C in a 5% CO₂ incubator. After the nanocomplex formation of the final 200 nM Cy3-labeled IL10-siRNA and peptides (20:1 N/P ratio), 160 μL of the nanocomplexes were applied to the cells in Opti-MEM™ for 4 hours. After washing twice with 200 μL of pre-warmed PBS, the cells were fixed using 200 μL of 10% formalin solution for 10 minutes. Then, the cells were treated serially with 200 μL of 0.1% Triton X-100 in PBS (0.1% PBST) for 10 minutes, then 200 μL of 2% BSA in 0.1% PBST at room temperature for 30 minutes. The cells were incubated in the Hoechst 33342 dye solution for 10 minutes in the absence of light. After washing twice with 200 μL of pre-warmed PBS, the cells were incubated in the Phalloidin dye solution at room temperature for 1 hour. After washing twice with 200 μL of pre-warmed PBS, the cells were observed at 200 × magnification by a fluorescence microscope (Ti-E; Nikon, Tokyo, Japan).

Cellular internalization observed using confocal microscopy

The cellular internalization of the siRNA/peptide nanocomplex was investigated using confocal images. HeLa cells of 2.0×10^4 were incubated in a 35-mm confocal dish (SPL Life Sciences Co., Ltd., Pocheon, South Korea) for 24 hours. After a 30-minute incubation of the final 50 nM Cy3-labeled siRNA and fluorescein (FITC)-labeled S-R15 (20:1 N/P ratio), the nanocomplex was applied to the cells for 4 hours. The nucleus and actin were stained using 5 μg/mL Hoechst 33342 and 100 nM SiR-actin kit, respectively. The intracellular localization and co-localization of siRNA and S-R15 were confirmed using fluorescence and a confocal microscope (Ti2; Nikon, Tokyo, Japan). Both of them were analyzed at the single-molecule level using super-resolution radial fluctuation (SRRF). Bright-field and fluorescence images were acquired at 900 × magnification. Image J software was used to merge the fluorescence images of Cy3, FITC, and SiR-actin [35].

Gene knockdown evaluation by quantitative RT-PCR

GAPDH mRNA expression reduced by nanocomplex was checked using quantitative real-time PCR. HeLa cells were seeded into a 24-well plate at a density of 1.0×10^5 cells per well. After overnight incubation at 37 °C in a 5% CO₂ incubator, 160 μL nanocomplex with the final 200 nM siRNA at 20:1 N/P ratio was applied to the cells in Opti-MEM™ for 5 hours. As a positive control, Lipofectamine™ 2000 reagent was used according to the provided protocols. After incubation for 5 hours, the media were replaced with 500 μL of fresh supplemented DMEM and incubated for an additional 19 hours. After washing three times with nuclease-free water, the total RNA of the cells was purified using Tri-RNA reagent following the manufacturer's protocol. The concentration and purity of purified RNA were measured using the Take3 plate as a nanodrop mode of a microplate reader (Epoch 2; BioTek Instruments, Inc., VT, USA). 100 ng of RNA were transcribed reversely to cDNA using ReverTra Ace® qPCR RT Master Mix with a gDNA Remover kit according to the manufacturer's protocol. The primer sequences of GAPDH and beta-actin that were

used are provided in Additional file 1: Table S3. After mixing 10 ng of cDNA, primers and THUNDERBIRD® SYBR® qPCR Mix according to the manufacturer's protocol, the PCR reaction was performed following the three-step cycle (Pre-denaturation; 95 °C for 60 seconds, Denaturation; 95 °C for 15 seconds, Annealing; 55 °C for 30 seconds, Extension; 72 °C for 60 seconds). GAPDH mRNA expression was analyzed using the QuantStudio 3 real-time PCR system (Applied Biosystems, CA, USA). The GAPDH mRNA expression was normalized by β -actin mRNA expression. The relative expression level was calculated using the $\Delta\Delta C_t$ method.

Endocytosis pathway study of nanocomplex

In a 6-well plate, HeLa cells were seeded at a density of 4.0×10^5 cells per well. After replacing the medium with Opti-MEM™, the cells were treated with each inhibitor for 30 minutes, i.e., Chlorpromazine (10 μ g/mL), Methyl- β -cyclodextrin (5 mM), Cytochalasin D (1 μ M), and Filipin III (1 μ g/mL) [36]. The nanocomplex of the final 200 nM Cy3-labeled siRNA and FITC-labeled S-R15 was self-assembled as described above. After adding 325 μ L of nanocomplex to the inhibitor-treated cells, the cells were incubated for 4 hours at 37 °C in a 5% CO₂ incubator. Cells with the fluorescence of Cy3 and FITC were analyzed using flow cytometry, as mentioned above.

Biocompatibility of the fusion peptides

The biocompatibility of the fusion peptides was assessed using CytoTox 96® non-radioactive cytotoxicity assay according to the manufacturer's protocol. Human dermal fibroblasts neonatal (HDFn) cells were cultured in DMEM medium supplemented with 10% FBS and 1% penicillin-streptomycin at 37 °C in a 5% CO₂ humidified incubator (Esco Micro Pte., Ltd., Changi, Singapore). HDFn cells were seeded on a 96-well plate at a density of 8.0×10^3 cells per well. After incubation over night, serially-diluted fusion peptides were added to cells at concentrations of 1, 0.5, 0.25, 0.125, and 0.0625 mg/mL. After incubation for 5 hours, 50 μ L aliquots of each well were transferred to each empty well of a 96-well plate. Then, 50 μ L of CytoTox 96® reagent were added to each well. Cells were incubated for 30 minutes at room temperature in light-free conditions. After adding 50 μ L of stop solution, absorbance was measured at 490 nm using a microplate reader.

***In vivo* pharmacokinetic study of nanocomplex**

All animal experiments were performed according to the protocol approved by the Institutional Animal Care and Use Committee (IACUC) of Incheon National University (INU-ANIM-2020-01). HeLa cells cultured over 90% confluency were prepared to $6.0 \times 10^6 - 1.0 \times 10^7$ cells in 100 μ L of fresh DMEM (w/o FBS). Five-week-old BALB/c-nude mice (Orientbio, Inc., Seongnam, South Korea) were anesthetized with 1.5–2% isoflurane in pure oxygen gas. Then, the cells were injected subcutaneously into both sides of the backs of the mice with a 1 mL insulin syringe. The formation of massive tumors was confirmed after 10 days. On day 10, the tumor-xenografted mice were anesthetized, and 29.78 μ L of 1 μ g free Cy3-labeled siRNA were injected intratumorally into the left tumor of a mouse. Then 29.78 μ L of 1 μ g Cy3-labeled siRNA in

the S-R11 nanocomplex (20:1 N/P ratio, as mentioned above) were injected intratumorally into the right tumor. The fluorescence intensity of Cy3 was visualized every hour up to 4 hours after injection using an *in vivo* fluorescence imaging system (FOBI, CELLGENTEK Co., Ltd., Cheongju, South Korea). The area, mean of intensity, and integrated density (area × mean of intensity) were quantified from the fluorescence images using NEOimage software.

Statistical analysis

The quantitative data were presented as mean ± standard deviation. The statistical significance of the differences was evaluated using a *p*-value less than 0.05, 0.01, and 0.001 calculated by a t-test.

Abbreviations

Glyceraldehyde 3-phosphate dehydrogenase (GAPDH), RNAi: RNA interference; siRNA: short-interfering RNA; RISC: RNA-induced silencing complexes; CPPs: Cell-penetrating peptides; TAT: Trans-activator of transcription; SPACE: Skin permeating and cell entering; S-R7: SPACE-R7; S-R11: SPACE-R11; S-R15: SPACE-R15; Lipo2000: LipofectamineTM 2000.

Declarations

Ethics approval and consent to participate

All animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC) of Incheon National University (INU-ANIM-2020-01).

Consent for publication

Not applicable.

Availability of data and materials

All data generated or analyzed during this study are included in this published article and its supplementary information files.

Competing interests

The authors declare that they have no competing interests.

Funding

This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning (NRF-2019R1F1A1063316).

Authors' contributions

YCR performed most of the experiments and wrote the manuscript. KK participated in some in vitro experiments. BCK and HMDW helped in data analysis. BHH supervised the whole study and revised the manuscript. All authors read and approved the final manuscript.

Acknowledgments

The authors are very grateful to prof. Won-Jong Rhee, who provided HeLa and HaCaT cells, and prof. Kyobum Kim, who provided HDFn.

References

1. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T: **Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells.** *Nature* 2001, **411**:494-498.
2. Whitehead KA, Langer R, Anderson DG: **Knocking down barriers: advances in siRNA delivery.** *Nat Rev Drug Discov* 2009, **8**:129-138.
3. Deng Y, Wang CC, Choy KW, Du Q, Chen J, Wang Q, Li L, Chung TK, Tang T: **Therapeutic potentials of gene silencing by RNA interference: principles, challenges, and new strategies.** *Gene* 2014, **538**:217-227.
4. Wang J, Lu Z, Wientjes MG, Au JL: **Delivery of siRNA therapeutics: barriers and carriers.** *AAPS J* 2010, **12**:492-503.
5. Sarett SM, Nelson CE, Duvall CL: **Technologies for controlled, local delivery of siRNA.** *J Control Release* 2015, **218**:94-113.
6. Lee SJ, Son S, Yhee JY, Choi K, Kwon IC, Kim SH, Kim K: **Structural modification of siRNA for efficient gene silencing.** *Biotechnol Adv* 2013, **31**:491-503.
7. Pathak A, Patnaik S, Gupta KC: **Recent trends in non-viral vector-mediated gene delivery.** *Biotechnol J* 2009, **4**:1559-1572.
8. Sinn PL, Sauter SL, McCray PB, Jr.: **Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors—design, biosafety, and production.** *Gene Ther* 2005, **12**:1089-1098.
9. Yin H, Kanasty RL, Eltoukhy AA, Vegas AJ, Dorkin JR, Anderson DG: **Non-viral vectors for gene-based therapy.** *Nat Rev Genet* 2014, **15**:541-555.
10. Zhou Z, Liu X, Zhu D, Wang Y, Zhang Z, Zhou X, Qiu N, Chen X, Shen Y: **Nonviral cancer gene therapy: Delivery cascade and vector nanoproperty integration.** *Adv Drug Deliv Rev* 2017, **115**:115-154.
11. Akhtar S: **Non-viral cancer gene therapy: beyond delivery.** *Gene Ther* 2006, **13**:739-740.
12. Levine RM, Scott CM, Kokkoli E: **Peptide functionalized nanoparticles for nonviral gene delivery.** *Soft Matter* 2013, **9**:985-1004.
13. Bae CS, Lee CM, Ahn T: **Encapsulation of Apoptotic Proteins in Lipid Nanoparticles to Induce Death of Cancer Cells.** *Biotechnol Bioproc E* 2020, **25**:264-271.
14. Vives E, Brodin P, Lebleu B: **A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus.** *J Biol Chem* 1997, **272**:16010-16017.

15. Yi A, Sim D, Lee YJ, Sarangthem V, Park RW: **Development of elastin-like polypeptide for targeted specific gene delivery in vivo.** *J Nanobiotechnology* 2020, **18**:15.
16. Kasai H, Inoue K, Imamura K, Yuvienco C, Montclare JK, Yamano S: **Efficient siRNA delivery and gene silencing using a lipopolypeptide hybrid vector mediated by a caveolae-mediated and temperature-dependent endocytic pathway.** *J Nanobiotechnology* 2019, **17**.
17. Koren E, Torchilin VP: **Cell-penetrating peptides: breaking through to the other side.** *Trends Mol Med* 2012, **18**:385-393.
18. Tang HY, Yin LC, Kim KH, Cheng JJ: **Helical poly(arginine) mimics with superior cell-penetrating and molecular transporting properties.** *Chem Sci* 2013, **4**:3839-3844.
19. Zeller S, Choi CS, Uchil PD, Ban HS, Siefert A, Fahmy TM, Mothes W, Lee SK, Kumar P: **Attachment of Cell-Binding Ligands to Arginine-Rich Cell-Penetrating Peptides Enables Cytosolic Translocation of Complexed siRNA.** *Chem Biol* 2015, **22**:50-62.
20. Sarett SM, Werfel TA, Chandra I, Jackson MA, Kavanaugh TE, Hattaway ME, Giorgio TD, Duvall CL: **Hydrophobic interactions between polymeric carrier and palmitic acid-conjugated siRNA improve PEGylated polyplex stability and enhance in vivo pharmacokinetics and tumor gene silencing.** *Biomaterials* 2016, **97**:122-132.
21. Guo F, Fu Q, Zhou K, Jin C, Wu W, Ji X, Yan Q, Yang Q, Wu D, Li A, Yang G: **Matrix metalloprotein-triggered, cell penetrating peptide-modified star-shaped nanoparticles for tumor targeting and cancer therapy.** *J Nanobiotechnology* 2020, **18**:48.
22. Langlet-Bertin B, Leborgne C, Scherman D, Bechinger B, Mason AJ, Kichler A: **Design and Evaluation of Histidine-Rich Amphipathic Peptides for siRNA Delivery.** *Pharm Res-Dordr* 2010, **27**:1426-1436.
23. Hsu T, Mitragotri S: **Delivery of siRNA and other macromolecules into skin and cells using a peptide enhancer.** *P Natl Acad Sci USA* 2011, **108**:15816-15821.
24. Mitchell DJ, Kim DT, Steinman L, Fathman CG, Rothbard JB: **Polyarginine enters cells more efficiently than other polycationic homopolymers.** *J Pept Res* 2000, **56**:318-325.
25. Najjar K, Erazo-Oliveras A, Mosior JW, Whitlock MJ, Rostane I, Cinclair JM, Pellois JP: **Unlocking Endosomal Entrapment with Supercharged Arginine-Rich Peptides.** *Bioconjug Chem* 2017, **28**:2932-2941.
26. Kumar S, Zakrewsky M, Chen M, Menegatti S, Muraski JA, Mitragotri S: **Peptides as skin penetration enhancers: Mechanisms of action.** *J Control Release* 2015, **199**:168-178.
27. Kim SW, Kim NY, Choi YB, Park SH, Yang JM, Shin S: **RNA interference in vitro and in vivo using an arginine peptide/siRNA complex system.** *J Control Release* 2010, **143**:335-343.
28. Kim TH, Ihm JE, Choi YJ, Nah JW, Cho CS: **Efficient gene delivery by urocanic acid-modified chitosan.** *J Control Release* 2003, **93**:389-402.
29. Tai W, Gao X: **Functional peptides for siRNA delivery.** *Advanced Drug Delivery Reviews* 2017, **110-111**:157-168.

30. Wang Y-H, Hou Y-W, Lee H-J: **An intracellular delivery method for siRNA by an arginine-rich peptide.** *J Biochem and Bioph Meth* 2007, **70**:579-586.
31. Chiu Y-L, Ali A, Chu C-y, Cao H, Rana TM: **Visualizing a Correlation between siRNA Localization, Cellular Uptake, and RNAi in Living Cells.** *Chem Biol* 2004, **11**:1165-1175.
32. Wang H, Chen W, Xie H, Wei X, Yin S, Zhou L, Xu X, Zheng S: **Biocompatible, chimeric peptide-condensed supramolecular nanoparticles for tumor cell-specific siRNA delivery and gene silencing.** *Chem Comm* 2014, **50**:7806-7809.
33. Schmidt N, Mishra A, Lai GH, Wong GC: **Arginine-rich cell-penetrating peptides.** *FEBS Lett* 2010, **584**:1806-1813.
34. Jones SW, Christison R, Bundell K, Voyce CJ, Brockbank SM, Newham P, Lindsay MA: **Characterisation of cell-penetrating peptide-mediated peptide delivery.** *Br J Pharmacol* 2005, **145**:1093-1102.
35. Schneider CA, Rasband WS, Eliceiri KW: **NIH Image to ImageJ: 25 years of image analysis.** *Nat Methods* 2012, **9**:671-675.
36. Dutta D, Donaldson JG: **Search for inhibitors of endocytosis: Intended specificity and unintended consequences.** *Cell Logist* 2012, **2**:203-208.

Figures




Figure 1

Characterization of siRNA/peptide self-assembled nanocomplexes: (a) Nanocomplex formation was checked using a gel retardation assay. The 21-bp siRNA was mixed with each peptide, i.e., SPACE, R11, TAT, S-R7, S-R11, and S-R15 at N/P ratios of 1:1, 5:1, 10:1, 20:1, 30:1, 40:1, 50:1, and 100:1. After incubation for 30 minutes, nanocomplexes mixed with a 6X loading dye were loaded into 2% (w/v) agarose gel stained with TopRed. Gel electrophoresis was run in TAE buffer at 100 V for 30 minutes. The gel was visualized through a ChemiDoc™ XRS+ System. The brightness and contrast of each picture were adjusted. (b) The sizes and zeta potentials of the nanocomplexes were measured using dynamic light scattering. The siRNA of 200 nM final concentration was incubated for 30 minutes with each peptide: SPACE, R11, S-R7, S-R11, and S-R15. After filtration and vortexing, each nanocomplex was loaded in the cell and analyzed through Nano ZS. Bars represented the average \pm standard deviation. The p-value was calculated using a t-test compared to that of SPACE (**; $p < 0.01$, independent $n = 3$). (c) siRNA stability was tested in serum. In the left pictures, each siRNA/peptide nanocomplex was incubated in 10% FBS for 24, 48, 72, and 96 hours. In the right images, each nanocomplex was incubated in 50% FBS for 4, 8, 12, 24, and 48 hours. Then, the samples were mixed with a 6X loading dye and loaded into a 2% (w/v) agarose gel stained with TopRed. Gel electrophoresis was run in the TAE buffer at 100 V for 25-

30 minutes. The gel was visualized through a gel documentation system. The brightness and contrast of each picture were adjusted for the best visualization.




Figure 2

Evaluation of the cellular uptake of siRNA/peptide nanocomplexes using fluorescence analysis: (a) Cellular uptake of Cy3-labeled IL10-siRNA/peptide nanocomplexes was evaluated using a fluorescence microscope. 200 nM siRNAs were delivered into 1.0×10^5 HeLa cells via PC: Lipofectamine™ 2000, SPACE, R11, S-R7, S-R11, and S-R15 (20:1 N/P ratio) for 4 hours. Nucleus and actin filaments were labeled using Hoechst 33342 (blue) and Phalloidin (green), respectively. The nanocomplex was observed in orange at 200 \times magnification (scale bar = 100 μ m). (b) Single-molecule images of the siRNA/S-R15 nanocomplex were acquired using a super-resolution radial fluctuation. 2.0×10^4 HeLa cells were incubated in a 35-mm confocal dish. The nanocomplex with the final 50 nM of siRNA and S-R15 (20:1 N/P ratio) was applied to the cells for 4 hours. Cy3-labeled IL10-siRNA and FITC-labeled S-R15 peptide were observed in magenta and green, respectively, at 900 \times magnification (scale bar = 1 μ m). Actin filaments were labeled using a SiR-actin kit (red). Fluorescence images of Cy3, FITC, and SiR-actin were merged using Image J software. Co-localization of the nanocomplex was visualized with arrowed white spot-like areas in a merged image (scale bar = 10 μ m). (c) Cellular internalization of the siRNA/S-R15 nanocomplex was confirmed using a Z-stack image. Actin filaments were labeled using a SiR-actin kit (red). The arrowed white spot-like areas demonstrated co-localization of siRNA and peptide in the cytoplasm at 900 \times magnification (scale bar = 5 μ m). The right and bottom images showed a cross-

sectional z-axis image of the arrowed white spot. (d) Cellular uptake of the Cy3-labeled IL10-siRNA/peptide nanocomplexes was evaluated using flow cytometry. 200 nM siRNAs were delivered into 3.0×10^5 HDFn cells via PC: Lipofectamine™ 2000, SPACE, R11, S-R7, S-R11, and S-R15 (20:1 N/P ratio) for 4 hours. Fluorescence cells of free siRNA and each condition were exhibited in red and green populations, respectively. The population of fluorescence-positive cells was expressed as a percentage.




Figure 3

Gene silencing activity and cell viability of fusion peptides: (a) Target GAPDH mRNA knockdown in HeLa and HaCaT by siRNA/peptide nanocomplexes were verified using quantitative RT-PCR. GAPDH-siRNAs of the final 200 nM concentration were delivered into each of the 1.0×10^5 HeLa cells in a 24-well plate using Lipofectamin™ 2000 as a commercialized positive control, SPACE, R11, S-R7, S-R11, and S-R15 (20:1 N/P ratio) for 5 hours. 100 ng of total RNAs isolated from cells were reverse-transcribed into cDNA. 10 ng of cDNA were used for the PCR reaction with GAPDH-specific forward and reverse primers. Relative mRNA expression levels were calculated using the $\Delta\Delta C_t$ method based on the housekeeping β -actin expression level. The relative expression levels of GAPDH mRNA were normalized by the mRNA expression of free siRNA. The data represented mean \pm standard deviation (*; $p < 0.05$, **; $p < 0.01$, and independent $n \geq 3$).

(b) Cell viability of three fusion peptides was examined using a lactate dehydrogenase (LDH) assay. Released LDH activities were measured from 8.0×10^3 HDFn cells under each fusion peptide at different concentrations (0, 0.0125, 0.025, 0.05, 0.1, and 0.2 mg/mL) in a 96-well plate using an LDH assay. LDH activity of cells treated with each peptide was normalized with the LDH activity without the peptide. The data represented mean \pm SD (independent repeat = 3). The p-value was calculated using a t-test.




Figure 4

Endocytosis pathway identification of the siRNA/S-R15 nanocomplex using various chemical inhibitors: 4.0×10^5 HeLa cells were pretreated with each endocytosis inhibitor (10 μ g/mL of chlorpromazine, 5 mM of methyl- β -cyclodextrin, 1 μ M of cytochalasin D, and 1 μ g/mL of filipin III) for 30 minutes. The final 100 nM concentration of the Cy3-labeled siRNA/FITC-labeled S-R15 nanocomplex (20:1 N/P ratio) was delivered into the cells for 4 hours. Each fluorescent cell population was counted using detached cells via FITC (upper row) and Cy3 (lower row) intensities, respectively. The fluorescence cell populations without and with each inhibitor are exhibited in red and green, respectively. The reduced population of fluorescence-positive cells was expressed as a percentage.




Figure 5

In vivo fluorescence imaging of intratumorally administered siRNAs to tumor-xenografted mice. The BALB/c-nude mice were anesthetized with 1.5 - 2% isoflurane, and 100 μ L of 6.0×10^6 - 1.0×10^7 HeLa cells were inoculated subcutaneously on both sides of the back. After 10 days, 1 μ g of free Cy3-labeled siRNA was administered intratumorally into the left tumor, and 1 μ g of Cy3-labeled siRNA/S-R11 (20:1 N/P ratio) nanocomplex was administered intratumorally into the right tumor site. (a) The Cy3 fluorescence intensity was observed every hour for 4 hours using an in vivo fluorescence imaging system. The left arrow indicated the fluorescence distribution of free siRNA, and the right arrow pointed that of the S-R11 nanocomplex. (b) Relative mean fluorescence intensity and (c) relative integrated density (area \times intensity unit) of each independent sample were analyzed using NEOimage™ software. The intensity at each time point was normalized with the initial intensity. The data represented mean \pm standard deviation (*; $p < 0.05$, **; $p < 0.01$ and independent $n = 4$).

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [siRNA delivery Additional file 1 final.docx](#)